A phase 1/2 clinical trial of the nitric oxide synthase inhibitor L-NMMA and taxane for treating chemoresistant triple-negative breast cancer-Reference-Cited by-同舟云学术

A phase 1/2 clinical trial of the nitric oxide synthase inhibitor L-NMMA and taxane for treating chemoresistant triple-negative breast cancer

Published:2021-12-15 Issue:624 Volume:13 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Chung Andrew W.¹²³^ORCID,Anand Kartik³^ORCID,Anselme Ann C.¹²³^ORCID,Chan Alfred A.⁴,Gupta Nakul⁵^ORCID,Venta Luz A.⁵^ORCID,Schwartz Mary R.⁶^ORCID,Qian Wei²³,Xu Yitian²³^ORCID,Zhang Licheng²³^ORCID,Kuhn John⁷,Patel Tejal³⁸,Rodriguez Angel A.⁹^ORCID,Belcheva Anna³,Darcourt Jorge³^ORCID,Ensor Joe³^ORCID,Bernicker Eric³^ORCID,Pan Ping-Ying²³^ORCID,Chen Shu Hsia²³^ORCID,Lee Delphine J.⁴¹⁰^ORCID,Niravath Polly A.³^ORCID,Chang Jenny C.²³^ORCID

Affiliation:

1. Texas A&M University Health Science Center, Bryan, TX 77807, USA.

2. Houston Methodist Research Institute, Houston, TX 77030, USA.

3. Houston Methodist Cancer Center, Houston, TX 77030, USA.

4. Lundquist Institute, Torrance, CA 90502, USA.

5. Department of Radiology, Houston Methodist Hospital, Houston, TX 77030, USA.

6. Houston Methodist Department of Pathology and Genomic Medicine, Houston, TX 77030, USA.

7. University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA.

8. Department of General Oncology MD Anderson Cancer Center, Houston, TX 77030, USA.

9. Austin Cancer Center, Austin, TX 78705, USA.

10. David Geffen School of Medicine at Los Angeles, CA 90095, USA.

Abstract